Surrozen Company Leadership

Management Team Effectiveness

The company has return on total asset (ROA) of -33.48 % which suggests that asset utilization is not generating returns above cost. This is in negative territory, trailing industry peers. Similarly, it shows a return on stockholder's equity (ROE) of -62.8 %, which suggests that shareholder capital is being eroded rather than compounded. As of now, Common Stock Shares Outstanding is anticipated to decline to approximately 2 M. In addition to that, Net Loss is anticipated to decline to approximately -51.6 M.

Stock Institutional Investors

At 220.11 Million, Surrozen sits in smaller-cap territory where institutional context matters most alongside valuation and volatility readings. The business currently sits in the Healthcare sector and the Biotechnology industry. Reading Surrozen holder concentration alongside float turnover and volatility adds the best context for understanding how smaller-cap ownership shapes price.

Insider Trading Activities

Corporate Filings

The majority of Surrozen's outstanding shares are owned by institutional holders. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors. Surrozen has approximately 96% of its outstanding shares held by institutional investors, 4% by insiders, and 0% in public hands.

Holders Distribution

Workforce Comparison

Insider Trading History

Notable Stakeholders

Workforce metrics tied to Surrozen offer a useful way to test whether headcount and economic output are moving in a productive direction. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.